Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, has agreed to an extension of its exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA (“Merck”), known as MSD outside the United States and Canada, to promote and distribute SIVEXTRO® (tedizolid phosphate) in the United States through December 31, 2026. SIVEXTRO is an oxazolidinone-class antibacterial indicated in adults and pediatric patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible Gram-positive microorganisms.
Nabriva has been marketing and distributing SIVEXTRO in the United States and certain of its territories as part of an exclusive agreement executed in July 2020 with Merck. Under the initial term of the agreement, Nabriva was solely responsible for marketing, sales, and distribution of SIVEXTRO in the United States through December 31, 2023. The amendment extends the agreement to December 31, 2026. The term of the agreement can be further extended by an additional three-year period, subject to mutual agreement.
Ted Schroeder, Chief Executive Officer of Nabriva, commented, “We are excited to announce the extension of our agreement with Merck to promote and distribute SIVEXTRO for at least an additional three years. This is a testament to our successful and collaborative relationship with Merck, and our strong commercial performance with SIVEXTRO. We look forward to building upon this momentum and expect SIVEXTRO be a significant contributor to the continued long-term growth of Nabriva.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!